Form 4: Neogenomics Executive Vice President Alicia C. Olivo Reports Stock Transactions
SEC Form 4
Alicia C. Olivo, EVP, GC & Business Development at Neogenomics, reports the vesting of restricted stock units and associated tax withholding, along with holdings of stock options and performance stock units.
Summary
- On May 11, 2025, Alicia C. Olivo, EVP, GC & Business Development at Neogenomics, reported transactions involving Neogenomics stock.
- Ms. Olivo acquired 6,503 shares of common stock upon the vesting of restricted stock units.
- She disposed of 1,584 shares to satisfy tax withholding obligations related to the vesting of these restricted stock units.
- Following these transactions, Ms. Olivo directly owns 49,620 shares of Neogenomics common stock.
- Ms. Olivo also holds various stock options and performance stock units with different exercise prices and expiration dates.
- These include options to buy common stock at prices ranging from $9.45 to $48.99, and performance stock units that may vest based on share growth and revenue growth goals.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive, with no inherent positive or negative sentiment.
Future Outlook
The vesting of restricted stock units and performance stock units is contingent upon continued service and the achievement of certain share growth and revenue goals.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the holdings and trading activity of company executives.
Stakeholder Impact
- The transactions have a minor impact on shareholders, reflecting changes in insider ownership.
- Employees holding similar equity grants may be interested in the vesting schedules and performance criteria.
Key Dates
| Date | Description |
|---|---|
| 09/30/2019 | Ms. Olivo was granted 1,394 stock options, vesting ratably over four years. |
| 05/01/2020 | Ms. Olivo was granted 1,024 stock options, vesting ratably over four years. |
| 05/01/2021 | Ms. Olivo was granted 516 stock options, vesting ratably over four years. |
| 08/01/2021 | Ms. Olivo was granted 1,117 stock options, vesting ratably over four years. |
| 05/01/2022 | Ms. Olivo was granted 22,222 stock options, vesting ratably over four years. |
| 09/01/2022 | Ms. Olivo was granted 55,332 stock options, vesting ratably over four years. |
| 05/11/2023 | Ms. Olivo was granted 36,508 stock options and 19,508 restricted stock units, vesting ratably over three years. |
| 02/23/2024 | Ms. Olivo was granted 42,344 stock options and 25,330 performance stock units, vesting ratably over three years. |
| 02/21/2025 | Ms. Olivo was granted 107,450 stock options and 63,238 restricted stock units, vesting ratably over three years. |
| 05/11/2025 | Reported transaction date: Vesting of 6,503 restricted stock units and disposition of 1,584 shares for tax withholding. |
| 05/11/2026 | Performance stock units granted on May 11, 2023, may vest. |
| 02/23/2027 | Performance stock units granted on February 23, 2024, may vest. |
| 02/23/2034 | Expiration date for stock options granted on February 23, 2024. |
| 02/21/2035 | Expiration date for stock options granted on February 21, 2025. |
Keywords
Neogenomics, Stock Options, Restricted Stock Units, Form 4, Beneficial Ownership, Insider Trading, Olivo, NEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.